As a result of the increasing aging of population in developed countries, chronic diseases with serious consequences for patients and healthcare system, such as chronic wounds, are emerging. Chronic wounds or ulcers are wounds that do not heal in 6 weeks.
In industrialized countries, about 1 to 2% of the population will have a problematic wound during their lifetime. For population over 65 years of age, chronic wounds, pressure ulcers, leg ulcers and diabetic foot ulcers cause significant public health problems, both from the point of view of the health of elderly patients, with a higher mortality rate than cancer, and from the point of view of the significant costs generated by these conditions, representing in Europe 2 to 4% of the healthcare budget. More than 800 000 people are estimated to be affected by chronic wounds in France.
The total estimated cost of care in France, in hospital and at home, amounts to 3.35 billion euros. The chronic wounds market is estimated at $25 billion in the USA in 2010 and 870 million euros in France, with annual growth of 10%.
Our mission today is to propose effective and adapted medical devices for the treatment of chronic pathologies (venous ulcers, diabetic foot ulcers, gingivitis, parondontitis…). By improving the healing time of chronic wounds, it is possible to improve patient’s quality of life on one hand, and to reduce the costs involved in the care journey on the other.
The bifunctional peptide, developed by Regentis-Pharma in collaboration with scientists, has strong assets to improve healing time. This peptide has a physiological action that will bring back balance within the scar tissues and promote an efficient and long-lasting healing.